Evaluating New Formulation of Therapeutic HSV-2 Vaccine
Status:
Completed
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
This study evaluates the reduction in viral shedding after vaccination with a new formulation
of GEN-003 in subjects with genital HSV-2 infection. Two-thirds of the participants will
receive GEN-003, one-third will receive placebo.